

*Meneses. Clara, Briegas. Daniel, Martín. Susana, M. Belén, B. Cristina, R. Lydia*

## Purpose

✦ To analyze posaconazole use, assessing the compliance with our Hospital Pharmacy and Therapeutics Committee (PTC) established criteria, and also its efficacy, safety and budget impact.


## Material and methods

✦ Retrospective study of patients under posaconazole treatment in our hospital between Sep 2013- Sep 2014.

✦ Data collecting: age, gender, diagnosis, indication, posology, treatment length, previous treatment lines, clinical analitics and microbiology, outcomes, adverse events, drug interactions and laboratory selling price.


## Results

### ✓ POPULATION



♂ 81 % ♀ 19 %  
 $\bar{X} = 58$  years

Expense per patient  
3000 €



- ✓ 90.9% posaconazole use met PTC criteria
- ✓ The outcome was positive for 81.8% of patients
- ✓ Two switched to other antifungal
- ✓ AE : raises in transaminases and direct bilirubin
- ✓ Main drug interactions: ranitidine and cyclosporin.

## Conclusion

PTC criteria was met in most of the cases, but posaconazole use for non approved indications represented an additional cost of 18155€, which remarks the need of a tight control of criteria compliance.